Drug-induced nonautoimmune hemolytic anemia
| Drug-induced nonautoimmune hemolytic anemia | |
| ICD-10 | D59.2 |
|---|---|
| ICD-9 | 283 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Drug-induced nonautoimmune hemolytic anaemia is a form of hemolytic anaemia.
Non-immune drug induced hemolysis can occur via oxidative mechanisms. This is particularly likely to occur when there is an enzyme deficiency in the antioxidant defence system of the red blood cells. An example is where antimalarial oxidant drugs like primaquine[1] damage red blood cells in Glucose-6-phosphate dehydrogenase deficiency in which the red blood cells are more susceptible to oxidative stress due to reduced NADPH production consequent to the enzyme deficiency.
Some drugs cause RBC (red blood cell) lysis even in normal individuals. These include dapsone[2] and sulfasalazine.
Non-immune drug-induced hemolysis can also arise from drug-induced damage to cell volume control mechanisms; for example drugs can directly or indirectly impair regulatory volume decrease mechanisms, which become activated during hypotonic RBC swelling to return the cell to a normal volume. The consequence of the drugs actions are irreversible cell swelling and lysis (e.g. ouabain at very high doses).
References
- ↑ Bowman ZS, Oatis JE, Whelan JL, Jollow DJ, McMillan DC (2004). "Primaquine-induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine". J. Pharmacol. Exp. Ther. 309 (1): 79–85. doi:10.1124/jpet.103.062984. PMID 14724225. Unknown parameter
|month=ignored (help) - ↑ Jollow DJ, Bradshaw TP, McMillan DC (1995). "Dapsone-induced hemolytic anemia". Drug Metab. Rev. 27 (1–2): 107–24. PMID 7641572.